Shortened Positive and Negative Symptom Scale as an Alternate Clinical Endpoint for Acute Schizophrenia Trials: Analysis from the US Food & Drug Administration

Gopalakrishnan, Mathangi; Farchione, Tiffany; Mathis, Mitchell; Zhu, Hao; Mehta, Mehul; Uppoor, Ramana; Younis, Islam

doi:10.1176/appi.prcp.20200003

Title: Shortened Positive and Negative Symptom Scale as an Alternate Clinical Endpoint for Acute Schizophrenia Trials: Analysis from the US Food & Drug Administration

Full Record
Other Related Research

Authors:

^[1]; Farchione, Tiffany ^[2]; Mathis, Mitchell ^[2]; Zhu, Hao ^[3]; Mehta, Mehul ^[3]; Uppoor, Ramana ^[3]; Younis, Islam ^[3]

Center for Translational Medicine University of Maryland Baltimore, Office of Clinical Pharmacology Office of Translational Sciences Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring Maryland
Division of Psychiatry Products Office of New Drugs Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring Maryland
Office of Clinical Pharmacology Office of Translational Sciences Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring Maryland

Publication Date:: Fri Nov 06 00:00:00 EST 2020

Sponsoring Org.:: USDOE

OSTI Identifier:: 1737724

Alternate Identifier(s):: OSTI ID: 1787074

Resource Type:: Published Article

Journal Name:: Psychiatric Research and Clinical Practice

Additional Journal Information:: Journal Name: Psychiatric Research and Clinical Practice Journal Volume: 3 Journal Issue: 1; Journal ID: ISSN 2575-5609

Publisher:: American Psychiatric Association Publishing

Country of Publication:: Country unknown/Code not available

Language:: English

Citation Formats


                    Gopalakrishnan, Mathangi, Farchione, Tiffany, Mathis, Mitchell, Zhu, Hao, Mehta, Mehul, Uppoor, Ramana, and Younis, Islam. Shortened Positive and Negative Symptom Scale as an Alternate Clinical Endpoint for Acute Schizophrenia Trials: Analysis from the US Food & Drug Administration.  Country unknown/Code not available: N. p., 2020. 
Web.  doi:10.1176/appi.prcp.20200003.

Copy to clipboard


                    Gopalakrishnan, Mathangi, Farchione, Tiffany, Mathis, Mitchell, Zhu, Hao, Mehta, Mehul, Uppoor, Ramana, & Younis, Islam. Shortened Positive and Negative Symptom Scale as an Alternate Clinical Endpoint for Acute Schizophrenia Trials: Analysis from the US Food & Drug Administration.  Country unknown/Code not available.  https://doi.org/10.1176/appi.prcp.20200003

Copy to clipboard


                    Gopalakrishnan, Mathangi, Farchione, Tiffany, Mathis, Mitchell, Zhu, Hao, Mehta, Mehul, Uppoor, Ramana, and Younis, Islam. Fri .  
"Shortened Positive and Negative Symptom Scale as an Alternate Clinical Endpoint for Acute Schizophrenia Trials: Analysis from the US Food & Drug Administration".  Country unknown/Code not available.  https://doi.org/10.1176/appi.prcp.20200003.

Copy to clipboard


                    
@article{osti_1737724,

  title        = {Shortened Positive and Negative Symptom Scale as an Alternate Clinical Endpoint for Acute Schizophrenia Trials: Analysis from the US Food & Drug Administration},

  author       = {Gopalakrishnan, Mathangi and Farchione, Tiffany and Mathis, Mitchell and Zhu, Hao and Mehta, Mehul and Uppoor, Ramana and Younis, Islam},

  abstractNote = {},

  doi          = {10.1176/appi.prcp.20200003},

  journal      = {Psychiatric Research and Clinical Practice},

  number       = 1,

  volume       = 3,

  place        = {Country unknown/Code not available},

  year         = {Fri Nov 06 00:00:00 EST 2020},

  month        = {Fri Nov 06 00:00:00 EST 2020}

}

Copy to clipboard

Journal Article:

Free Publicly Available Full Text

Publisher's Version of Record
https://doi.org/10.1176/appi.prcp.20200003

Other availability

Search WorldCat to find libraries that may hold this journal

Save / Share:

Export Metadata

Save to My Library

Similar Records in DOE PAGES and OSTI.GOV collections:

Patient-Reported Outcomes in Pediatric Cancer Registration Trials: A US Food and Drug Administration Perspective

Journal Article Murugappan, Meena N. ; King-Kallimanis, Bellinda L. ; Reaman, Gregory H. ; ... - JNCI, Journal of the National Cancer Institute

Abstract Pediatric patient-reported outcome (PRO) data can help inform the US Food and Drug Administration’s (FDA’s) benefit-risk assessment of cancer therapeutics by quantifying symptom and functional outcomes from the patient’s perspective. This study assessed use of PROs in commercial pediatric oncology trials submitted to the FDA for regulatory review. FDA databases were searched to identify pediatric oncology product applications approved between 1997 and 2020. Sponsor-submitted documents were reviewed to determine whether PRO data were collected, which instruments were used, and the quality of collected data (ie, sample size, completion rates, and use of fit-for-purpose instruments). The role ofmore »« less
https://doi.org/10.1093/jnci/djab087
Patient-Reported Outcomes in Pediatric Cancer Registration Trials: A US Food and Drug Administration Perspective

Journal Article Murugappan, Meena N. ; King-Kallimanis, Bellinda L. ; Reaman, Gregory H. ; ... - JNCI, Journal of the National Cancer Institute

Pediatric patient-reported outcome (PRO) data can help inform the US Food and Drug Administration’s (FDA’s) benefit-risk assessment of cancer therapeutics by quantifying symptom and functional outcomes from the patient’s perspective. This study assessed use of PROs in commercial pediatric oncology trials submitted to the FDA for regulatory review. FDA databases were searched to identify pediatric oncology product applications approved between 1997 and 2020. Sponsor-submitted documents were reviewed to determine whether PRO data were collected, which instruments were used, and the quality of collected data (ie, sample size, completion rates, and use of fit-for-purpose instruments). The role of PROs in eachmore »« less
https://doi.org/10.1093/jnci/djab087
Aggregation and analysis of secondary pharmacology data from investigational new drug submissions at the US Food and Drug Administration

Journal Article Dodson, Andrew ; Mi, Kevin ; Russo, Daniel P. ; ... - Journal of Pharmacological and Toxicological Methods
https://doi.org/10.1016/j.vascn.2021.107098
Analysis of secondary pharmacology assays received by the US Food and Drug Administration

Journal Article Scott, Christina ; Dodson, Andrew ; Saulnier, Muriel ; ... - Journal of Pharmacological and Toxicological Methods

Secondary pharmacology studies are a time-efficient and cost-effective method for determining the safety profile of a potential new drug before it enters human trials. The results of these multi-target screens are commonly submitted with Investigational New Drug (IND) applications, but there currently is little guidance on how such information is presented and which targets are chosen for testing. In this study, we expand on our previous analysis of secondary pharmacology reports by manually curating and analyzing all secondary pharmacology results received by the FDA received as part of an IND submission. A total of 1120 INDs submitted by 480 sponsorsmore »« less
https://doi.org/10.1016/j.vascn.2022.107205
Adverse Events Involving Radiation Oncology Medical Devices: Comprehensive Analysis of US Food and Drug Administration Data, 1991 to 2015

Journal Article Connor, Michael J. ; Department of Radiation Oncology, University of California Irvine School of Medicine, Irvine, California ; Marshall, Deborah C. ; ... - International Journal of Radiation Oncology, Biology and Physics

Purpose: Radiation oncology relies on rapidly evolving technology and highly complex processes. The US Food and Drug Administration collects reports of adverse events related to medical devices. We sought to characterize all events involving radiation oncology devices (RODs) from the US Food and Drug Administration's postmarket surveillance Manufacturer and User Facility Device Experience (MAUDE) database, comparing these with non–radiation oncology devices. Methods and Materials: MAUDE data on RODs from 1991 to 2015 were sorted into 4 product categories (external beam, brachytherapy, planning systems, and simulation systems) and 5 device problem categories (software, mechanical, electrical, user error, and dose delivery impact).more »« less
https://doi.org/10.1016/J.IJROBP.2016.08.050

Similar Records